<DOC>
	<DOCNO>NCT01265745</DOCNO>
	<brief_summary>Valortim name experimental drug volunteer receive study . Valortim may also call MDX-1303 . Experimental mean drug yet approve Food Drug Administration ( FDA ) . Valortim monoclonal antibody ( laboratory-made immune system molecule ) treatment inhalation anthrax ( infection start lung ) . Valortim work attach part anthrax toxin prevent toxin damage cell . This study conduct see Valortim give 120 minute safe tolerable . This study take place five part : Screening Phase , Check-in Phase ( day arrive Quintiles start study ) , Treatment Phase ( time receive study medication ) , Follow-up Phase ( time receive study medication ) Final Visit .</brief_summary>
	<brief_title>Dose Escalation Study Valortim® ( MDX-1303 ) Administered Intravenously ( IV ) Healthy , Normal Subjects</brief_title>
	<detailed_description>Twenty-eight subject recruit enter one three dose group 1mg/kg , 5mg/kg , 10mg/kg placebo . Subjects stagger dose one three group randomly assign receive Valortim saline . Subjects reside clinical trial Phase I Unit Day -1 Day 2 . After discharge Day 2 , subject return Phase I unit 7 time specified time point additional 130 day post-dosing ( 133 day total participation check-in Day -1 ) placebo .</detailed_description>
	<mesh_term>Anthrax</mesh_term>
	<criteria>1.Subject must read , understood , provide write informed consent 2.Subjects generally good health , base upon prestudy medical history , physical examination , laboratory test ECG 3.Laboratory screen value ( i.e. , hematology , clinical chemistry urinalysis test ) must within studydefined range 4.No detectable antibody B. anthracis Protective Antigen ( PAIgG ) measure ELISA test study Screening 5.Women childbearing potential sexually active male may enrol protocol specific contraceptive practice meet 6.Agreement receive vaccination Day 1 29 day post dose . Vaccination B. anthracis prohibit study.8.Body Mass Index ( BMI ) ≥ 19 ≤ 30 . 9 . Abstinence alcohol 24 hour prior study drug 1 . Prior know suspected exposure B. anthracis 2 . Prior vaccination B. anthracis 3.Prior exposure Valortim part previous clinical trial 4.Immunoglobulin E ( IgE ) level screen upper limit normal per laboratory 's reference range 5 . History drug alcohol abuse , i.e. , treat either inpatient outpatient facility within 12 month study Screening 6 . Outward sign active allergy upper respiratory infection 7 . History dizziness faint upon stand ( orthostatic hypotension ) , opinion Investigator , may interfere safety evaluation 8 . Positive drug result and/or positive alcohol result time study Screening Day 1</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Phase I</keyword>
</DOC>